Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan 3;7(4):E857-64.
doi: 10.1208/aapsj070483.

Shear-induced variability in the United States Pharmacopeia Apparatus 2: modifications to the existing system

Affiliations

Shear-induced variability in the United States Pharmacopeia Apparatus 2: modifications to the existing system

Jennifer L Baxter et al. AAPS J. .

Abstract

The hydrodynamics within the United States Pharmacopeia Apparatus 2 have been shown to be highly non-uniform with a potential to yield substantial variability in dissolution rate measurements. Through the use of readily available engineering tools, several geometric modifications to the device were evaluated in this study. Specifically, we examined the influence of impeller clearance, agitator type (radial and axial), and vessel geometry (PEAK vessel) on the fluid flow properties and their relation to measured dissolution rates. Increasing the impeller clearance was observed to exacerbate the heterogeneity in shear and would likely result in greater variability in dissolution measurements. Altering the impeller type was shown to yield changes in the hydrodynamic behavior; however, the overall properties and problems with the test remain the same. Use of the PEAK vessel was observed to reduce shear heterogeneity in the regions where tablets are most likely to visit during testing; however, higher shear rates may result in the inability to discriminate between true differences in dissolution rates.

PubMed Disclaimer

References

    1. Banakar UV. Pharmaceutical Dissolution Testing. New York, NY: Marcel Dekker Inc; 1992.
    1. Cox DC, Furman WB. Systematic error associated with Apparatus 2 of theUSP dissolution test I: effects of physical alignment of the dissolution apparatus. J Pharm Sci. 1982;71:451–452. doi: 10.1002/jps.2600710419. - DOI - PubMed
    1. Moore TW, Hamilton JF, Kerner CM. Dissolution testing: limitations of theUSP prednisone and salicylic acid calibrator tablets. Pharmaceutical Forum. 1995;21:1387–1396.
    1. Qureshi SA, McGilveray IJ. Typical variability in drug dissolution testing: study withUSP and FDA calibrator tablets and a marketed drug (Glibenclamide) product. Eur J Pharm Sci. 1999;7:249–258. doi: 10.1016/S0928-0987(98)00034-7. - DOI - PubMed
    1. Qureshi SA, Shabnam J. Cause of high variability in drug dissolution testing and its impact on setting tolerances. Eur J Pharm Sci. 2001;12:271–276. doi: 10.1016/S0928-0987(00)00174-3. - DOI - PubMed

Publication types

LinkOut - more resources